New developments in pancreatic cancer

We began by looking at a study exploring what support GPs need to start using new pancreatic cancer tests as soon as they become available. We then heard about the world’s first breath test for pancreatic cancer. To finish, we found out about the development of a decision risk tool for early diagnosis of pancreatic cancer among new-onset diabetes in UK primary care. 

Agenda:

• 18.00 – 18.05: Welcome and introduction – Chris Macdonald, Head of Research, Pancreatic Cancer UK
• 18.05 – 18.15: Developing a toolkit to assess GP’s readiness to adopt new pancreatic cancer tests – Dr Patrick Kierkegaard, Team Leader – Cancer Technology Catalyst & Research Fellow, Imperial College London
• 18.15 – 18.25: World’s first breath test – Professor George Hanna, Head of Department of Surgery and Cancer, Imperial College London
• 18.25 – 18.35: Decision risk tool for early diagnosis in new-onset diabetes – Dr Ashley Clift, Clinical Research Fellow, University of Oxford
• 18.35 – 18.55: Q&A
• 19.00 – 19.00: Close

Who is this session for?

This event is open to all health professionals working with pancreatic cancer patients. It is particularly relevant to GPs and health professionals working in primary care.

Watch the recording here

We began by finding out everything you need to know about genomic medicine and the impact on your practice. We then explored the logistics, challenges, risks and benefits including when to refer and who to refer, and the impact on treatment options.

Agenda:

• 09.00 – 09.05: Welcome and introduction – Rachel Richardson, Specialist Pancreatic Cancer Nurse, Pancreatic Cancer UK
• 09.05 – 09.40: Genomic medicine – Dr Fieke Froeling, Consultant Medical Oncologist and Clinical Senior Lecturer in Pancreatic Cancer at the CRUK Beatson Institute
• 09.40 – 09.55: Questions
• 09.55 – 10.00: Close

Who is this session for?

This event is open to all health professionals working with pancreatic cancer patients. It is particularly relevant to CNSs, oncology teams, consultants, genetic counsellors and GPs.

Watch the recording here

We began with an overview of SABR, the use of this treatment for patients with unresectable pancreatic cancer and an update on clinical trials in this area.  

Then we had an overview of focus ultrasound, its potential treatment for people with pancreatic cancer, and current trials. 

Agenda: 

• 09.00 – 09.05: Welcome and introduction – Dianne Dobson, Specialist Pancreatic Cancer Nurse, Pancreatic Cancer UK 
• 09.05 – 09.30: Update on SABR – Dr Ganesh Radhakrishna, Consultant Clinical Oncologist, The Christie Hospital 
• 09.30 – 09.55: Update on focus ultrasound – Dr Keaton Jones, NIHR Academic Clinical Lecturer at Nuffield Department of Surgical Sciences, University of Oxford and Katherine Gordon-Quayle, Research Nurse, Churchill Hospital 
• 09.55 – 10.00: Close 

Who is this session for? 

This event is open to all health professionals looking after pancreatic cancer patients having treatment. It is particularly relevant to CNSs and oncology teams. 

Watch the recording here 

What platform will this session be hosted on? 

These events will be held on Zoom Webinar. After you book, you will receive an email via Zoom with the joining details. You can join on a computer, laptop, tablet or smartphone – any device with an internet connection. 

If you don’t have access to the internet, you can also dial in from a standard telephone. 

Will I receive a certificate of attendance? 

Everyone who joins the sessions live on the day will get access to their certificate of attendance upon filling in the feedback form. Certificates are only available to live attendees. 

Will the session be recorded? 

Yes – where the speakers are happy to be recorded. After the events, we will email all registrants with a link to the recording and presentation slides. So if you’re unable to join the live session(s), you will be able to catch up at a later date. For the best experience, we recommend joining live. 

D0 I need to attend all three sessions?

No. You’re very welcome to attend all three events to hear about the latest developments in different areas but you’re not required to attend all three and they’re not linked together in terms of content.